Results 101 to 110 of about 8,937 (172)

Quantum Chemical Studies of Anti-Blood Cancer Agents, II. [PDF]

ACS Omega
Boča R, Štofko J, Ladická M, Rajnák C.   +3 more
europepmc   +1 more source

Bortezomib in Patients Who Fail BTKi in Waldenström Macroglobulinaemia. [PDF]

Hematol Rep
Khwaja J, Japzon N, Gatto S, Lindsay J, Kyriakou C, D'Sa S.   +5 more
europepmc   +1 more source

Clinical management and outcomes for 51 Pugs reportedly diagnosed with protein-losing enteropathy using VetCompass primary care veterinary data. [PDF]

J Small Anim Pract
Kathrani A, Brodbelt DC, Church DB, O'Neill DG.   +3 more
europepmc   +1 more source

Virtual Screening and Zebrafish Phenotype-Based Evaluation Argues Against Repurposing 4-Phenylbutyrate for STXBP1-Related Disorders. [PDF]

Pharmacol Res Perspect
Frick A, Whyte-Fagundes P, Baraban SC.
europepmc   +1 more source

Real-world disease characteristics and frontline treatments used in chronic lymphocytic leukaemia in Bulgaria: An observational cohort study (DESCRIBE). [PDF]

J Int Med Res
Graklanov V, Radinoff A, Micheva I, Efraim ME, Donchev M, Yankova T, Slavcheva-Popova V, Naneva S, Hadjiev E, Gercheva-Kyuchukova L, Petrova-Latkova M, Nikolov I, Nenov A, Ostojić A, Krasteva S, Grudeva-Popova Z.   +15 more
europepmc   +1 more source

Complex genetic landscape in CLL: Clinical impact on patients' survival and insights into the altered molecular pathways. [PDF]

Mol Ther Oncol
Caputo C, Donadelli M, Scupoli M, D'Arena G, Pietrantuono G, Giudice A, Giliberti A, Volpe S, Sperlongano R, Cautela D, Scafuri B, Facchiano A, Cossu AM, Bocchetti M, Misso G, Lombardi A, Caraglia M, Grimaldi A.   +17 more
europepmc   +1 more source

EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation. [PDF]

Hemasphere
Eichhorst B, Ghia P, Bosch F, Clifford R, Gregor M, Guieze R, Kater AP, Niemann CU, Pospisilova S, Robak T, Schuh A, Stamatopoulos K, Tadmor T, York N.   +13 more
europepmc   +1 more source

BTK Inhibition in Hematology: From CLL/SLL to Emerging Applications Across B-Cell and Immune Disorders. [PDF]

Biomolecules
Duminuco A, De Luca P, Stanzione G, Caruso LA, Lavenia G, Scarso S, Garibaldi B, Palumbo FE, Vetro C, Palumbo GA.   +9 more
europepmc   +1 more source

ATM inhibition decreases ERK activation and is synergistic with ibrutinib in primary chronic lymphocytic leukemia cells. [PDF]

Blood Adv
Kost SEF, Saleh A, Brown J, Yuan SH, Kuzio B, Yang L, Banerji V, Gibson SB, Johnston JB, Katyal S.   +9 more
europepmc   +1 more source